Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 14
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Levine, Stephen Z. and Leucht, Stefan 2014. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials. Schizophrenia Research, Vol. 156, Issue. 1, p. 107.

    Morrison, A. P. Hutton, P. Shiers, D. and Turkington, D. 2012. Antipsychotics: is it time to introduce patient choice?. The British Journal of Psychiatry, Vol. 201, Issue. 2, p. 83.

    Remington, Gary Foussias, George Agid, Ofer Fervaha, Gagan Takeuchi, Hiroyoshi and Hahn, Margaret 2014. The neurobiology of relapse in schizophrenia. Schizophrenia Research, Vol. 152, Issue. 2-3, p. 381.

    McCutcheon, R. A. 2013. Commissions, coercion and choice. The Psychiatrist, Vol. 37, Issue. 5, p. 179.

    Holmes, R D Tiwari, A K and Kennedy, J L 2016. Mechanisms of the placebo effect in pain and psychiatric disorders. The Pharmacogenomics Journal,

    Thomas, N. Hayward, M. Peters, E. van der Gaag, M. Bentall, R. P. Jenner, J. Strauss, C. Sommer, I. E. Johns, L. C. Varese, F. Garcia-Montes, J. M. Waters, F. Dodgson, G. and McCarthy-Jones, S. 2014. Psychological Therapies for Auditory Hallucinations (Voices): Current Status and Key Directions for Future Research. Schizophrenia Bulletin, Vol. 40, Issue. Suppl 4, p. S202.

    Schennach, Rebecca Meyer, Sebastian Seemüller, Florian Jäger, Markus Schmauss, Max Laux, Gerd Pfeiffer, Herbert Naber, Dieter Schmidt, Lutz G. Gaebel, Wolfgang Klosterkötter, Joachim Heuser, Isabella Maier, Wolfgang Lemke, Matthias R. Rüther, Eckart Klingberg, Stefan Gastpar, Markus Musil, Richard Möller, Hans-Jürgen and Riedel, Michael 2012. Response trajectories in “real-world” naturalistically treated schizophrenia patients. Schizophrenia Research, Vol. 139, Issue. 1-3, p. 218.

    Van Dorn, Richard A. Desmarais, Sarah L. Tueller, Stephen J. Jolley, Jennifer M. Johnson, Kiersten L. and Swartz, Marvin S. 2013. Drug and alcohol trajectories among adults with schizophrenia: Data from the CATIE study. Schizophrenia Research, Vol. 148, Issue. 1-3, p. 126.

    Pelayo-Terán, J. M. Diaz, F. J. Pérez-Iglesias, R. Suárez-Pinilla, P. Tabarés-Seisdedos, R. de León, J. and Crespo-Facorro, B. 2014. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychological Medicine, Vol. 44, Issue. 01, p. 37.

    Chen, Lei Johnston, Joseph A Kinon, Bruce J Stauffer, Virginia Succop, Paul Marques, Tiago R and Ascher-Svanum, Haya 2013. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry, Vol. 13, Issue. 1,

    Gilbert, Elsa Mérette, Chantal Jomphe, Valérie Émond, Claudia Rouleau, Nancie Bouchard, Roch-Hugo Roy, Marc-André Paccalet, Thomas and Maziade, Michel 2014. Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment. European Archives of Psychiatry and Clinical Neuroscience, Vol. 264, Issue. 4, p. 333.

    Power, Robert A. Muthén, Bengt Henigsberg, Neven Mors, Ole Placentino, Anna Mendlewicz, Julien Maier, Wolfgang McGuffin, Peter Lewis, Cathryn M. and Uher, Rudolf 2012. Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. Journal of Psychiatric Research, Vol. 46, Issue. 10, p. 1333.

    Sacchetti, E Magri, C Minelli, A Valsecchi, P Traversa, M Calza, S Vita, A and Gennarelli, M 2016. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. The Pharmacogenomics Journal,

    Hutton, P. Morrison, A. P. Yung, A. R. Taylor, P. J. French, P. and Dunn, G. 2012. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatrica Scandinavica, Vol. 126, Issue. 1, p. 1.


The different trajectories of antipsychotic response: antipsychotics versus placebo

  • T. R. Marques (a1), T. Arenovich (a2), O. Agid (a2), G. Sajeev (a2), B. Muthén (a3), L. Chen (a4), B. J. Kinon (a4) and S. Kapur (a1)
  • DOI:
  • Published online: 20 October 2010

It is generally accepted that antipsychotics are more effective than placebo. However, it remains unclear whether antipsychotics induce a pattern or trajectory of response that is distinct from placebo. We used a data-driven technique, called growth mixture modelling (GMM), to identify the different patterns of response observed in antipsychotic trials and to determine whether drug-treated and placebo-treated subjects show similar or distinct patterns of response.


We examined data on 420 patients with schizophrenia treated for 6 weeks in two double-blind placebo-controlled trials using haloperidol and olanzapine. We used GMM to identify the optimal number of response trajectories; to compare the trajectories in drug-treated versus placebo-treated patients; and to determine whether the trajectories for the different dimensions (positive versus negative symptoms) were identical or different.


Positive symptoms were found to respond along four distinct trajectories, with the two most common trajectories (‘Partial responder’ and ‘Responder’) accounting for 70% of the patients and seen proportionally in both drug- and placebo-treated. The most striking drug–placebo difference was in the ‘Dramatic responders’, seen only among the drug-treated. The response of negative symptoms was more modest and did not show such distinct trajectories.


Trajectory models of response, rather than the simple responder/non-responder dichotomy, provide a better statistical account of how antipsychotics work. The ‘Dramatic responders’ (those showing >70% response) were seen only among the drug-treated and make a significant contribution to the overall drug–placebo difference. Identifying and studying this subset may provide specific insight into antipsychotic action.

Corresponding author
*Address for correspondence: S. Kapur, M.B.B.S., Ph.D., F.R.C.P.C., Dean and Professor, PO Box 053, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

O Agid , S Kapur , T Arenovich , RB Zipursky (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 12281235.

CM Beasley Jr., T Sanger , W Satterlee , G Tollefson , P Tran , S Hamilton (1996 a). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berlin) 124, 159167.

CM Beasley Jr., G Tollefson , P Tran , W Satterlee , T Sanger , S Hamilton (1996 b). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111123.

DL Garver , JA Holcomb , JD Christensen (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry 61, 964972; quiz 973.

S Kapur , T Arenovich , O Agid , R Zipursky , S Lindborg , B Jones (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry 162, 939946.

BJ Kinon , L Chen , H Ascher-Svanum , VL Stauffer , S Kollack-Walker , JL Sniadecki , JM Kane (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230240.

S Leucht , R Busch , J Hamann , W Kissling , JM Kane (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57, 15431549.

SZ Levine , J Rabinowitz (2008). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624632.

B Muthén , HC Brown (2009). Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Statistics in Medicine 28, 33633385.

B Muthén , CH Brown , K Masyn , B Jo , ST Khoo , CC Yang , CP Wang , S Kellam , J Carlin , J Liao (2002). General growth mixture modeling for randomized preventive interventions. Biostatistics (Oxford, England) 3, 459475.

B Muthén , K Shedden (1999). Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55, 463469.

JE Overall , DR Gorham (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799812.

FM Quitkin , JG Rabkin , D Ross , JW Stewart (1984). Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 41, 782786.

R Rothschild , FM Quitkin (1992). Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychotherapy and Psychosomatics 58, 170177.

HH Stassen , J Angst , D Hell , C Scharfetter , A Szegedi (2007). Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of Clinical Psychiatry 68, 11951205.

HH Stassen , A Delini-Stula , J Angst (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology 3, 127135.

JW Stewart , FM Quitkin , PJ McGrath , J Amsterdam , M Fava , J Fawcett , F Reimherr , J Rosenbaum , C Beasley , P Roback (1998). Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives General Psychiatry 55, 334343.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *